Since 1 March 2021, the Pharmaceutical Register of the Eurasian Patent Office (EAPO) is available on the official website of the Eurasian Patent Office. The Register contains information on Eurasian patents protecting active substances of drugs.

The rating particularly states that Andrey is “well versed in all aspects of intellectual property and can hammer out favourable outcomes in difficult disputes in the life sciences, fast-moving consumer goods and high-technology spheres” and Boris is “a trusted adviser to numerous pharmaceutical companies on both the patent and trademark sides, and has further know-how in advertising and data protection.

Lidings’ managing partner Andrey Zelenin heading the firm’s Pharmaceuticals and Healthcare industry practice and partner Boris Malakhov, Head of the Intellectual Property practice of the firm, run a special webinar on the key market developments in the healthcare and life sciences sector in Russia.

On January 5, 2021 the Decree of the Government of the Russian Federation No. 3718-r dated December 31, 2020 (the Decree) was published. In accordance with the Decree, Pharmasintez JSC, a Russian generic company, has been granted a 1-year compulsory license to use the inventions of the US companies Gilead Sciences Inc. and Gilead Pharmasset LLC protecting Remdesivir subject to a “fair compensation”¹.

Partner and Head of the Lidings’ Intellectual Property practice Boris Malakhov will take part in an annual conference entitled Intellectual Property: Court Practice, IP transactions, Future of IP organized by Pravo.ru.

Eurasian Virtual Pharmaceutical Summit will take place on October 14-21, 2020. Lidings’ managing partner Andrey Zelenin and partner of the Firm’s Intellectual Property practice Boris Malakhov will speak at the event.

Partner of the Lidings’ Intellectual Property practice Boris Malakhov will take part in the online IP conference DISTANT & DIGITAL – major event on intellectual property and LegalTech in Russia and CIS. The conference will take place on 8-9 September 2020.